( JERUSALEM--(BUSINESS WIRE)--Mar 7 2007...)BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality,Health

JERUSALEM--(BUSINESS WIRE)--Mar 7, 2007 - BioLineRx Ltd. (TASE:BLRX), Israel's leading drug development company, reported today pre-clinical data from trials of BL-1040 demonstrating that BL-1040 is effective in preventing deterioration of the myocardium after a myocardial infarction (MI), thereby reducing left ventricle dilatation and eventual heart failure in a pig model. Professor Jonathan Leor, MD, Director of the Neufeld Cardiac Research Institute at Sheba Medical Center in Israel, presented pre-clinical data on BL-1040 at the Cardiovascular Revascularization Therapies (CRT) conference, held March 7-9, 2007 in Washington, D.C.

"We are encouraged by these results, as BL-1040 is the first injectable liquid polymer being developed to provide mechanical support to damaged heart tissues following MI. The data so far have shown that this therapy may increase cardiac performance or contractility and prevent further damage," stated Professor Leor.

"We believe there is a great unmet medical need for this product to prevent cardiac tissue damage in the risky period following heart attack," commented Morris C. Laster, MD, CEO of BioLineRx. "We look forward to advancing BL-1040 to Phase I/II trials in the second quarter of 2007 and plan to work closely with the U.S. FDA medical devices division to determine the clinical plan for BL-1040."

The data presented at the CRT conference comprised a study in 21 pigs that underwent an acute MI, and then received an intra-coronary administration of BL-1040. The results showed that BL-1040 attenuated infarct expansion and prevented left ventricle dilatation. The intracoronary administration of BL-1040 was feasible and safe, without causing arrhythmias, toxic effects or vascular obstruction.

About BL-1040

BL-1040 is a biodegradable liquid polymer intended to provide mechanical support to damaged heart tissue and increase cardiac output. BL-1040 is admin
'"/>

Page: 1 2 3
Related medicine technology :

1. BioLineRx Presents Data From Successful Phase I Trial for BL-1020 in Schizophrenia at American Psychiatric Association Conference
2. BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming Clinical Conferences
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting